Antimicrobial Susceptibility Testing Market Report 2025

This Antimicrobial Susceptibility Testing market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The antimicrobial susceptibility testing market size has grown strongly in recent years. It will grow from $4.36 billion in 2024 to $4.66 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to rise in healthcare expenditure, aging population, awareness and education, regulatory support, economic growth.

The antimicrobial susceptibility testing market size is expected to see strong growth in the next few years. It will grow to $5.81 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing prevalence of drug-resistant infections, rise in healthcare infrastructure, growing emphasis on drug discovery, rise in disposable income. Major trends in the forecast period include automation and robotics, ai and machine learning, multiplexing, telemedicine integration, rapid ast methods.

The increasing prevalence of infectious diseases worldwide has fueled the growth of the antimicrobial susceptibility testing market. Infectious diseases are caused by organisms such as bacteria, viruses, fungi, and parasites. Bacterial infections can lead to conditions like bacterial pneumonia, tuberculosis, and other diseases caused by viruses, such as smallpox and AIDS. For instance, in March 2024, the Centers for Disease Control and Prevention, a U.S.-based national public health agency, reported that in 2023, out of 9,573 TB cases with known birth origins, 7,259 (76%) were among non-U.S.-born individuals, marking an 18% increase from the 6,177 cases reported in 2022. Therefore, the rising incidence of infectious diseases is propelling the growth of the antimicrobial susceptibility testing market.

The mounting prevalence of chronic diseases is expected to be a significant factor fueling the growth of the antimicrobial susceptibility testing market. Chronic illnesses, which are enduring and often incurable conditions necessitating ongoing medical management, render individuals more vulnerable to various infections. Antimicrobial susceptibility testing plays a crucial role in identifying the specific pathogens responsible for these infections and determining the most effective antibiotics against them. For example, a report by the Centers for Disease Control and Prevention (CDC) in July 2022 highlighted that a considerable proportion of the American population grapples with chronic diseases, thereby increasing susceptibility to infections such as chronic lung diseases, heart disease, stroke, and diabetes. This rise in chronic conditions is a driving force behind the market's growth.

A notable trend emerging in the antimicrobial susceptibility testing market is the adoption of rapid testing methods aimed at preventing antibiotic misuse and ensuring more effective treatments. Various techniques, such as Fluorescence in situ hybridization (FISH) and QuickFish technology (OpGen), utilize probes targeting RNA to rapidly identify and test microbial susceptibility. For instance, the antimicrobial susceptibility testing system developed by Genefluidics Inc uses an electrochemical biosensor to measure bacterial growth by quantifying 16s rRNA molecules, ensuring swift and accurate testing. This emphasis on rapid testing methods stands as a key trend in the evolution of the antimicrobial susceptibility testing market, catering to the pressing need for timely and accurate analysis to guide effective treatment strategies.

Major companies in the antimicrobial susceptibility testing market are advancing through the development of innovative products like the First Point-of-Care (POC) Testing System. This groundbreaking system is designed to identify the presence or absence of bacteria and evaluate the efficacy of antimicrobials by utilizing urine samples from patients suspected of having urinary tract infections (UTIs). The introduction of this system marks a significant stride in the realm of antimicrobial susceptibility testing (AST) technologies. Its primary advantage lies in expediting the commencement of targeted antimicrobial therapy for patients diagnosed with infections. For example, in June 2023, Sysmex Corporation, a Japan-based company specializing in manufacturing reagents and equipment for clinical tests, introduced a rapid antimicrobial susceptibility testing system. This innovative system employs a unique and proprietary microfluidic technology, delivering AST results in as little as 30 minutes from the initiation of the measurement process. This is a substantial reduction compared to the several days typically required for conventional AST methods. The system's swift and accurate results revolutionize the efficiency and timeliness of treatment initiation, catering to the urgent needs of patients requiring targeted antimicrobial therapy.

Major companies operating in the antimicrobial susceptibility testing market include BioMérieux SA, Becton Dickinson and Company, Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories Inc., Accelerate Diagnostics Inc., Hi-Media Laboratories, Creative Diagnostics, Merck KGaA, Roche Diagnostics Limited, Alifax Holding S.p.A., Synbiosis Ltd., Zhuhai DL Biotech Co. Ltd., Mast Group Ltd., ELITechGroup, Genefluidics Inc., Condalab, QuantaMatrix Inc., Bruker Corporation, Eurofins Scientific SE, Liofilchem s.r.l., Hardy Diagnostics, Micromax Technologies, Bioanalyse GmbH, Lab M Limited, Microbiologics Inc., Quidel Corporation, R-Biopharm AG, SSI Diagnostica A/S, VWR International LLC, ZeptoMetrix Corporation.

North America was the largest region in the antimicrobial susceptibility testing market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the antimicrobial susceptibility testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Antimicrobial susceptibility testing (AST) is a laboratory procedure conducted by clinical professionals to determine the most effective antimicrobial specimen for individual patients. The market for antimicrobial susceptibility testing involves the sales of such testing services provided by entities, including organizations, sole traders, and partnerships, engaged in laboratory services.

The primary types of AST procedures include antibacterial testing, antifungal testing, antiparasitic testing, and others. Antifungal susceptibility testing assesses the ability of a specific organism to grow in vitro in the presence of a particular drug. AST products utilized in testing encompass manual antimicrobial susceptibility testing products, automated laboratory instruments, and other consumables. These products find applications in diagnostics, drug discovery and development, and epidemiology. Antimicrobial susceptibility testing is employed by hospitals, diagnostic centers, pharmaceutical and biotechnology companies, research and academic institutes, as well as clinical research organizations (CROs).

The antimicrobial susceptibility testing market research report is one of a series of new reports that provides antimicrobial susceptibility testing market statistics, including antimicrobial susceptibility testing industry global market size, regional shares, competitors with an antimicrobial susceptibility testing market share, detailed antimicrobial susceptibility testing market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial susceptibility testing industry. This antimicrobial susceptibility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the antimicrobial susceptibility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The antimicrobial susceptibility testing (AST) market includes revenues earned by dilution susceptibility tests and disc diffusion susceptibility tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.